Partial profits from $CTMX (-5,05%) realized and the capital invested in $RIGL (-1,24%) invested.
Rigel Pharmaceuticals, Inc. is a US biotechnology company specializing in the development and provision of development and delivery of novel therapies for hematologic disorders and cancer. and cancer. The company focuses on compounds that interfere with immunological and oncological signaling pathways to better treat diseases with high unmet medical need. Rigel Pharmaceuticals, Inc.
🧬 Core business and scientific focus
- Development of innovative drugs for blood diseasesespecially immunological and oncological disorders.
- Research into targeted therapies that modulate specific signaling pathways in order to influence pathological cell processes.
- Pipeline includes several clinical programs and approved products such as Tavalisse, Gavreto and Rezlidhia. Rigel Pharmaceuticals, Inc.
💊 Products and approved therapies
- Tavalisse®: Treatment of certain immunological blood diseases.
- Gavreto®: treatment option for certain forms of cancer.
- Rezlidhia®: use in oncology.
- All products have full prescribing information and in some cases boxed warnings. Rigel Pharmaceuticals, Inc.
📈 Current company development
Rigel reported for the year 2025 a total revenue of around USD 294.3 millionincluding Record product sales of USD 65.4 million in the fourth quarter of 2025. This shows clear operational momentum and growing market acceptance of the products. FinanzNachrichten.de
🏢 Company profile in brief
- Registered office: USA
- Industry: Biotechnology / Pharmaceuticals
- Listed on the stock exchange: NASDAQ (Ticker: RIGL)
- Focus: Hematology, oncology, immunological diseases
- Mission: Improving the quality of life of patients through innovative therapies. Rigel Pharmaceuticals, Inc.
The current business figures of Rigel Pharmaceuticals show strong growth, high profitability and solid operational development. The key points can be clearly identified to provide a sound picture of the company's situation.
📊 Key results for 2025
- Total turnover 2025: approx. USD 294.3 milliona growth of 60 % compared to 2024. trendonify.com
- Net product sales:
USD 232.0 million for the full year. Yahoo Finance - Q4/2025 sales: approx. USD 69.8 millionthereof USD 65.4 million product sales (record value). Rigel Pharmaceuticals, Inc.
- Net profit for 2025:
USD 367.0 millioninfluenced by a non-cash tax income of USD 245.9 million. trendonify.com
📈 Classification of the figures
Turnover development
The sales growth of 60% is exceptionally strong and shows that Rigel is successfully placing its products on the market. The high product sales in the fourth quarter in particular underline strong demand.
Profitability
The high annual profit is partly distorted by a one-off tax effect. Operationally, however, the company is showing a clear improvement, as product sales are rising continuously.
Pipeline & future prospects
- The Phase 1b study on R289 in MDS patients is proceeding according to plan, which strengthens the potential for future indications. Rigel Pharmaceuticals, Inc.
- The combination of a growing portfolio and clinical pipeline points to sustainable growth.
🧭 Overall assessment
Rigel currently presents itself as a a dynamically growing biotech company with:
The special tax effect should be taken into account when assessing profitability, but does not change the positive operating performance.
- strongly increasing sales,
- solid product demand,
- a developing pipeline,
- and a very strong balance sheet in 2025.
